Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Double-Blind, Placebo-Controlled Multi-dose Study to Investigate Etokimab (ANB020) Activity in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Trial Profile

A Phase 2 Double-Blind, Placebo-Controlled Multi-dose Study to Investigate Etokimab (ANB020) Activity in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Etokimab (Primary)
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors AnaptysBio
  • Most Recent Events

    • 30 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 13 Aug 2018 New trial record
    • 07 Aug 2018 According to an AnaptysBio media release, the Company plans to initiate this study by the end of 2018 and anticipates top-line data in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top